Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Greenstone Strikes Sildenafil Deal

Viagra Authorized Generic Offered Via Roman Digital Healthcare Clinic

Executive Summary

Pfizer’s Greenstone subsidiary has struck a deal with digital healthcare clinic Roman to offer members access to its authorized generic version of Viagra.

You may also be interested in...

Pfizer To Merge Off-Patent Business With Mylan

Pfizer has announced plans to merge its off-patent unit with Mylan, creating a new generics and biosimilars giant in the US.

Pfizer competes on US Viagra

Pfizer is taking steps to compete with Teva’s recently-launched generic rival to Viagra (sildenafil) in the US, both through the introduction of its own authorised generic and through programmes aimed at supporting patients who still wish to use the brand. The originator’s authorised generic – launched through its Greenstone subsidiary (Generics bulletin, 15 December 2017, page 13) – is priced at around US$30-35 per tablet.

Teva offers services to support sildenafil

Teva has accompanied its launch of a US rival to Pfizer’s Viagra (sildenafil) tablets with a range of “wraparound services to improve patient access”. The generic will compete with a brand that had annual US sales of around US$1.4 billion according to Iqvia, as well as an authorised generic that has just been launched by Pfizer.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts